Eliquis now has the unique distinction of being the only new anticoagulant to reduce stroke, major bleeding, and death versus the gold standard warfarin in atrial fibrillation patients (the largest commercial opportunity, in our view).
As for whether it works for sharpening the brain or minimizing damage from a stroke "the jury is out, " says Catherine Ulbricht, co-founder of Natural Standard Research Collaboration, a Cambridge, Mass.